Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Aug 16, 2018 08:11 PM IST | Source: PTI

AstraZeneca Pharma India gets DCGI nod to market cancer drug in India

The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.

Representative Image
Representative Image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer.

The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.

The tablets are a patented product of the AstraZeneca group, it added.

"The import and market permission for olaparib is a significant milestone for women in India living with platinum-sensitive relapsed ovarian cancer and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases," AstraZeneca Pharma India MD Gagan Singh said.

Shares of AstraZeneca Pharma India today closed at Rs 1,710.30 per scrip on BSE, up 1.59 per cent from their previous close.
First Published on Aug 16, 2018 08:06 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant